Neuren Pharmaceuticals (ASX:NEU) - Stock Price, News & Analysis

Resumen acción NEU

Neuren Pharmaceuticals Limited, empresa biofarmacéutica, desarrolla medicamentos para el tratamiento de trastornos neurológicos.

Acerca de la empresa

NEU fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	6/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 93.1% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 18.27%

Los beneficios aumentaron un 85270.1% el año pasado

Los analistas coinciden en que el precio de las acciones subirá un 36.8%

Análisis de riesgos

No se han detectado riesgos en NEU a partir de nuestros controles de riesgos.

Competidores de Neuren Pharmaceuticals Limited

Vitura Health

ASX:VIT

AU$109.4m

Probiotec

ASX:PBP

AU$233.8m

ECS Botanics Holdings

ASX:ECS

AU$28.3m

Vita Life Sciences

ASX:VLS

AU$135.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Neuren Pharmaceuticals
Historical stock prices
Current Share Price	AU$20.72
52 Week High	AU$25.95
52 Week Low	AU$10.02
Beta	1.99
1 Month Change	-1.94%
3 Month Change	-12.57%
1 Year Change	54.74%
3 Year Change	1,396.03%
5 Year Change	1,733.63%
Change since IPO	180.00%

Noticias y actualizaciones recientes

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Recent updates

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04

Rentabilidad de los accionistas

	NEU	AU Pharmaceuticals	Mercado AU
7D	-0.4%	0.6%	0.9%
1Y	54.7%	44.5%	7.7%

Rentabilidad frente al sector: NEU superó al sector Australian Pharmaceuticals , que obtuvo un rendimiento del 60.1% el año pasado.

Rentabilidad vs. Mercado: NEU superó al mercado Australian, que obtuvo un rendimiento del 4.3% el año pasado.

Volatilidad de los precios

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Average Weekly Movement	7.0%
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.3%

Precio estable de las acciones: NEU no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NEU (11%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	n/a	Jon Pilcher	www.neurenpharma.com

Neuren Pharmaceuticals Limited, empresa biofarmacéutica, desarrolla medicamentos para el tratamiento de trastornos neurológicos. Su principal producto es la trofinetida, que se encuentra en fase III de ensayo clínico para el tratamiento del síndrome de Rett, y ha completado la fase II de ensayo clínico para tratar el síndrome X frágil. La empresa desarrolla el NNZ-2591, que ha completado el ensayo clínico de fase I para el tratamiento de los síndromes de Phelan-McDermid, Angelman, Pitt Hopkins y Prader-Will.

Resumen de fundamentos de Neuren Pharmaceuticals Limited

¿Cómo se comparan los beneficios e ingresos de Neuren Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de NEU
Capitalización bursátil	AU$2.65b
Beneficios(TTM)	AU$157.08m
Ingresos (TTM)	AU$231.94m

16.8x

Ratio precio-beneficio (PE)

11.4x

Ratio precio-ventas (PS)

¿Está NEU sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NEU
Ingresos	AU$231.94m
Coste de los ingresos	AU$26.75m
Beneficio bruto	AU$205.19m
Otros gastos	AU$48.11m
Beneficios	AU$157.08m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	1.23
Margen bruto	88.47%
Margen de beneficio neto	67.72%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado NEU a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción NEU

Recompensas

Análisis de riesgos

Competidores de Neuren Pharmaceuticals Limited

ASX:VIT

AU$109.4m

ASX:PBP

AU$233.8m

ASX:ECS

AU$28.3m

ASX:VLS

AU$135.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Recent updates

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Consensus estimates of losses per share improve by 47%

Price target increased to AU$6.62

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Consensus forecasts updated

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Independent Non-Executive Chairman recently bought AU$50k worth of stock